BiotechTube
BrainRepair

BrainRepair

Munich, Germany· Est.
brainrepair.eu
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.7M

Overview

BrainRepair is a pioneering biotech developing autologous cord blood stem cell therapies for pediatric brain injury, a condition that can lead to cerebral palsy. The company is clinically advanced, with its lead product having secured Orphan Drug Designation from the EMA and classification as an Advanced Therapy Medicinal Product - Tissue Engineered Product (ATMP-TEP). Its mission addresses a significant unmet medical need with no current curative treatments, positioning it at the forefront of regenerative medicine for neurological conditions in children.

NeurologyPediatrics

Technology Platform

Autologous cord blood-derived stem cell therapy platform for neuroregeneration, classified as an ATMP-TEP (Advanced Therapy Medicinal Product - Tissue Engineered Product) by the EMA.

Funding History

2
Total raised:$4.7M
Seed$3.5M
Grant$1.2M

Opportunities

Addresses a massive unmet need in cerebral palsy with no curative treatments, representing a multi-billion dollar market.
Holds valuable Orphan Drug and ATMP designations in Europe, providing regulatory incentives and potential market exclusivity.
Success in the initial indication could enable expansion into other pediatric neurological injuries.

Risk Factors

High clinical risk associated with demonstrating efficacy in complex neurological outcomes.
Significant funding required to advance through clinical trials, with continued operation dependent on successful capital raises.
Autologous cell therapy presents complex and costly manufacturing and logistics challenges.

Competitive Landscape

The competitive landscape for disease-modifying treatments for cerebral palsy is nascent but evolving. BrainRepair appears to have a first-mover regulatory advantage in Europe with its orphan designation. Competition includes other academic and biotech entities exploring allogeneic cord blood cells, mesenchymal stem cells (MSCs), and other neuroregenerative approaches for neonatal brain injury.

More companies in Cell & Gene Therapy →More companies in Germany →